Navigation Links
OncoGenex Reports First Quarter Financial Results
Date:5/6/2010

cancer ("NSCLC") are on track to initiate in the third quarter of 2010, the second half of 2010 and early 2011, respectively."

Recent Business Highlights:

OGX-011

    -   The European Medicines Agency confirmed that they are in overall
        agreement with our Phase III development plan for OGX-011 in patients
        with CRPC.
    -   Two peer-reviewed manuscripts were published that further explain the
        biological function of clusterin, its role in promoting tumor
        resistance to cancer treatment, and the role of an inhibitor of
        clusterin such as OGX-011, to enhance the effectiveness of cancer
        therapies. One of the co-authors to these manuscripts, Dr. Martin
        Gleave, is also the Company's Chief Scientific Advisor.

OGX-427

    -   Grant funding was secured for a randomized, investigator-sponsored
        Phase II trial of OGX-427 when administered as a monotherapy to
        patients with CRPC.
    -   Two peer-reviewed manuscripts were published that provide further
        insight into the mechanism of action of heat shock protein 27
        (Hsp27). OGX-427 is designed to reduce levels of Hsp27.
    -   Final results from a Phase 1 study involving OGX-427 will be
        presented as part of the Scientific Program in a General Poster
        Session with discussion at the ASCO 2010 Annual Meeting. These final
        data, including results combining OGX-427 with docetaxel, will update
        preliminary data that was featured in an oral presentation at the
        ASCO 2009 meeting.

Corporate Highlights

    -   Dr. Jack Goldstein and Ms. H. Stewart Parker were appointed to the
        board of directors. Dr. Goldstein joins the board as chairman. In
        addition, Dr. Martin Mattingly has agreed to stand for election at
        the Company's upcoming
'/>"/>
SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. OncoGenex Pharmaceuticals to Webcast Discussion of Financial Results for Fourth Quarter and Fiscal Year 2009
2. OncoGenex Pharmaceuticals to Present at RBC Capital Markets Healthcare Conference
3. Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex Late Stage Innovative Treatment for Multiple Oncology Indications
4. OncoGenex Pharmaceuticals to Host Investor Conference Call at 8:30 a.m. ET, December 21, 2009
5. OncoGenex Reports Third Quarter 2009 Financial Results
6. OncoGenex Pharmaceuticals to Release Third Quarter 2009 Financial Results
7. OncoGenex Pharmaceuticals CEO Named Canadas Pacific Ernst & Youngs Entrepreneur Of The Year(R) in the Health Sciences Category
8. OncoGenex Pharmaceuticals to Webcast Presentations at September Investor Conferences
9. OncoGenex Pharmaceuticals Announces Issuance of Key Patent for OGX-011
10. OncoGenex Reports Second Quarter 2009 Financial Results
11. OncoGenex Pharmaceuticals to Release Second Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... (PRWEB) February 27, 2015 The ... system (Nexera UC) can sequentially analyze up to ... combined with high-sensitivity detection of targets by mass ... designed to fulfill the measurement requirements of a ... food products, drug delivery and search for disease ...
(Date:2/27/2015)... CA (PRWEB) February 27, 2015 Cytokinetics, ... forces on February 28 with patients and health care ... awareness for Rare Disease Day®. Rare Disease Day ... and calling attention to the special challenges faced by ... them. , “Cytokinetics is proud to stand alongside patients ...
(Date:2/26/2015)... 2015 On behalf of biotech client ... Wilentz, Goldman & Spitzer, P.A. (Wilentz) secured a significant ... Inc. in excess of $10 million. The jury determined ... and that it improperly hired one or more of ... for judgment notwithstanding the verdict, a new trial, and ...
(Date:2/26/2015)... LA JOLLA, Calif. , Feb. 26, 2015 /PRNewswire/ ... ), a biopharmaceutical company leading the discovery and development ... Kleanthis G. Xanthopoulos , Ph.D., President and Chief Executive ... the Cowen and Company 35 th Annual Healthcare ... EST.  The conference is being held at the Boston ...
Breaking Biology Technology:Shimadzu Corporation Launches Nexera UC - The World’s Foremost Unified Chromatography System 2Shimadzu Corporation Launches Nexera UC - The World’s Foremost Unified Chromatography System 3Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 2Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 3Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 4Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 5Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 6Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 3Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 2Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 3
... with YWCA & Roche to Educate Patients on, ... and a Career -, NEW YORK, March 10 ... Careers, a non-profit program,founded by Cosmetic Executive Women Foundation, ... the hundreds of thousands of people,living with cancer on ...
... J.D., joins BrainCells, Board of ... ... (BCI), a,biopharmaceutical company utilizing its platform technology to identify and,develop compounds ... nervous system (CNS) diseases, announced today that it has,completed a $30 ...
... CITY, Calif., March 10, Otsuka Pharmaceutical Co., Ltd. ... today announced the closing of the,previously announced transaction ... Busulfex(R) (busulfan), including trademarks, patents,intellectual property and related ... Busulfex is an oncologic product marketed and sold ...
Cached Biology Technology:First-Ever 'Cancer and Careers' Seminar Debuts in Orange County 2First-Ever 'Cancer and Careers' Seminar Debuts in Orange County 3BrainCells Inc. Completes $30 Million Initial Closing of Series B Financing 2Otsuka Pharmaceutical and PDL BioPharma Close Sale of IV Busulfex 2Otsuka Pharmaceutical and PDL BioPharma Close Sale of IV Busulfex 3Otsuka Pharmaceutical and PDL BioPharma Close Sale of IV Busulfex 4
(Date:2/24/2015)... 2015 Research and Markets ( ... "Global 2D Gesture Recognition Market 2015-2019" ... analysts forecast the Global 2D Gesture Recognition market ... the period 2014-2019 The increased demand ... one of the major trends in the market. ...
(Date:2/13/2015)... TAIPEI , Feb. 13, 2015 ... service company that aims to transform cancer genomic ... announced that the company has raised US$ 8 million ... Based in Taipei, Taiwan ... tests, ACTDrug™, ACTOnco™. With the aim to implement ...
(Date:2/10/2015)... WALTHAM, Mass., Feb. 10, 2015  Alere Inc. ... announced its financial results for the quarter ended ... Executive Officer and President of Alere said, "We ... refocussing Alere as the global leader in rapid ... closing the Alere Health divestiture in early January ...
Breaking Biology News(10 mins):Global 2D Gesture Recognition Market 2015-2019 with Cognitec Systems, CogniVue, eyeSight Mobile Technologies & PointGrab Dominating 2ACT Genomics Raises $8 Million in its First Private Funding Round 2Alere Inc. Announces Fourth Quarter 2014 Results 2Alere Inc. Announces Fourth Quarter 2014 Results 3Alere Inc. Announces Fourth Quarter 2014 Results 4Alere Inc. Announces Fourth Quarter 2014 Results 5Alere Inc. Announces Fourth Quarter 2014 Results 6Alere Inc. Announces Fourth Quarter 2014 Results 7Alere Inc. Announces Fourth Quarter 2014 Results 8Alere Inc. Announces Fourth Quarter 2014 Results 9Alere Inc. Announces Fourth Quarter 2014 Results 10Alere Inc. Announces Fourth Quarter 2014 Results 11Alere Inc. Announces Fourth Quarter 2014 Results 12Alere Inc. Announces Fourth Quarter 2014 Results 13Alere Inc. Announces Fourth Quarter 2014 Results 14Alere Inc. Announces Fourth Quarter 2014 Results 15Alere Inc. Announces Fourth Quarter 2014 Results 16Alere Inc. Announces Fourth Quarter 2014 Results 17Alere Inc. Announces Fourth Quarter 2014 Results 18Alere Inc. Announces Fourth Quarter 2014 Results 19Alere Inc. Announces Fourth Quarter 2014 Results 20Alere Inc. Announces Fourth Quarter 2014 Results 21Alere Inc. Announces Fourth Quarter 2014 Results 22Alere Inc. Announces Fourth Quarter 2014 Results 23Alere Inc. Announces Fourth Quarter 2014 Results 24Alere Inc. Announces Fourth Quarter 2014 Results 25Alere Inc. Announces Fourth Quarter 2014 Results 26Alere Inc. Announces Fourth Quarter 2014 Results 27Alere Inc. Announces Fourth Quarter 2014 Results 28Alere Inc. Announces Fourth Quarter 2014 Results 29Alere Inc. Announces Fourth Quarter 2014 Results 30Alere Inc. Announces Fourth Quarter 2014 Results 31Alere Inc. Announces Fourth Quarter 2014 Results 32Alere Inc. Announces Fourth Quarter 2014 Results 33Alere Inc. Announces Fourth Quarter 2014 Results 34
... Antibiotic resistance is a growing human health concern. ... other pharmaceuticals to be present in surface waters ... underlying groundwater. In a recent article in the ... at Colorado State University (CSU) describe a study ...
... potential risks growing" If so, who or ... newswiresenvironmental and consumer organizations, scientists, law makers, or ... decide to cover a nanotechnology story, especially one ... correspondents face special challenges reporting on a technology ...
... Antarctica, Nov. 28, 2007 -- A second season in ... exceeded all expectations, according to the co-chief scientists of ... (Nov. 21), the drilling team passed the 1,000-meter mark ... in McMurdo Sound, and with a remarkable recovery rate ...
Cached Biology News:Manure management reduces levels of antibiotics and antibiotic resistance genes 2Nanotechnology and the media: The inside story 2ANDRILL's 2nd Antarctic drilling season exceeds all expectations 2ANDRILL's 2nd Antarctic drilling season exceeds all expectations 3
Neuropilin-2 Purified Anti-Rat clone 54, Isotype Mouse IgG 1 , 150 µg Consult technical datasheet for details....
CBF-B (G-2)...
HSV-2 gD (0191)...
... Dynabeads Epoxy (4.5 m). Hydrophobic naked ... Ideal for coupling of antibodies for cell ... coupling with covalent binding of primary amine ... (SH)) occurring within 16-20 hours. Coupling reactions ...
Biology Products: